earnings
confidence high
sentiment neutral
materiality 0.60
BioAtla Q1 net loss $15.3M; cash $32.4M; Mec-V shows 59% 2-year OS in mKRAS NSCLC
BioAtla, Inc.
2025-Q1 EPS
reported -$0.26
vs consensus -$17.68
▲ beat
(+98.5%)
- Net loss $15.3M vs $23.2M YoY; R&D expenses down to $12.4M from $18.9M.
- Cash $32.4M at March 31, 2025; expects runway beyond key readouts in 1H 2026.
- BA3182 Phase 1 dose-escalation ongoing; data readout mid-2025; three patients dosed at 300 µg.
- Mec-V in mKRAS NSCLC shows 67% 1-year and 59% 2-year landmark OS (SOC <20%).
- Oz-V in HPV+ SCCHN: 45% ORR (5/11), 100% disease control; Fast Track discussions with FDA.